Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
M&A / Property Routine +

Knight Announces Early Warning Filing Regarding Shares of Crescita

By The Northwire Desk — AI Analysis Jun 05, 2026 · 18:00 GUD · 8.61 KNIGHT THERAPEUTICS INC.
GUD · Price

Executive Summary

  • Knight Therapeutics Inc. reports the closing of a previously announced plan of arrangement whereby ClinActiv Holdings Inc. acquired all outstanding common shares of Crescita Therapeutics Inc.
  • Knight Therapeutics, which previously held approximately 10.4% of Crescita’s shares, has fully divested its stake and is no longer an insider or subject to early warning reporting requirements.
  • The transaction was completed for a cash consideration of $0.80 per share.

Key Details

  • Transaction Type: Plan of arrangement (full acquisition)
  • Target Company: Crescita Therapeutics Inc.
  • Acquirer/Purchaser: ClinActiv Holdings Inc. (via wholly-owned subsidiary)
  • Consideration: $0.80 cash per share for all issued and outstanding common shares
  • Knight's Pre-Closing Position: Held 1,935,489 shares, representing approximately 10.4% of Crescita’s issued and outstanding shares
  • Knight's Post-Closing Position: Holds 0 shares, ceased to be an insider, and is no longer subject to early warning reporting under Regulation 62-103
  • Regulatory Context: Release disseminated to comply with Regulation 62-103 respecting the Early Warning System and Related Take-Over Bid and Insider Reporting Issues
  • Crescita Head Office: 2805 Place Louis-R-Renaud, Laval, Québec, H7V 0A3
  • Investor Contact: Samira Sakhia (President & CEO) and Arvind Utchanah (CFO) at Knight Therapeutics Inc. ([email protected])
Read the original news release →

More from KNIGHT THERAPEUTICS INC.

Jun 17, 2026 · 17:30

Debt-free balance sheet achieved ahead of schedule, but the credit win was already telegraphed by Q1 cash flow and priced into the +11% run-up.

Other May 27, 2026 · 18:00

LATAM Expansion Validates Growth Strategy But FX and Generic Risks Loom

Other May 08, 2026 · 06:30

Knight Therapeutics scores Brazilian approval for TAVALISSE just as record sales lift stock to all‑time high

Regulatory May 07, 2026 · 06:30

Knight Therapeutics Q1 Earnings Beat Drives Guidance Hike Amidst LATAM Expansion

Earnings Mar 19, 2026 · 07:30

Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results

Earnings Mar 17, 2026 · 17:30

Knight wins Anvisa approval for Minjuvi use in Brazil

Regulatory